Dario Neri

Dario Neri
Zurich (CHE)


Dario Neri, professor at the ETH Zurich since 1996 and co-founder of the Swiss-Italian biotech company Philogen, has worked for many years on the development of novel therapeutic strategies, leading various antibody products into advanced clinical trials for the treatment of cancer and of rheumatoid arthritis. Following his graduation in Chemistry at the Scuola Normale Superiore of Pisa, he obtained a doctoral degree in Chemistry in 1992 at the ETH Zürich, receiving the ETH Silver Medal for his dissertation. His career continued with an EU Bridge Bursary, working as post-doctoral researcher at the Cambridge Centre for Protein Engineering, Medical Research Council Centre, from 1992 till 1996.

Dario Neri’s approach to immunotherapy has opened novel prospects for the therapy of cancer. Other research interests of his group include the development of DNA-encoded chemical libraries, as well as the use of mass spectrometry methodologies for target discovery and for MHC peptidome analysis. His work has resulted in over 300 peer-reviewed publications in scientific journals.

Prof. Neri received the ISOBM Abbott Prize 2000, the Amgen-Dompe’ Biotec Award 2000, the Mangia d’Oro 2001, the Prous Award 2006 of the European Federation of Medicinal Chemistry, the Robert-Wenner-Prize 2007 of the Swiss Cancer League, the SWISS BRIDGE Award 2008, the 2011 Prix Mentzer of the French Society for Medicinal Chemistry (RICT), the Phoenix Award 2014 for Pharmacology and Clinical Pharmacy and an ERC Advanced Grant in 2015.

Latest News


Workshop Registration for HFYLS 5 paticipants is possible from now on. Places are limited and will be assigned on a first-come-first-serve basis.




Join us now on